Compare PRTS & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRTS | SCLX |
|---|---|---|
| Founded | 1995 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto & Home Supply Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.7M | 35.2M |
| IPO Year | 2006 | 2020 |
| Metric | PRTS | SCLX |
|---|---|---|
| Price | $8.33 | $5.25 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $0.50 | N/A |
| AVG Volume (30 Days) | ★ 84.6K | 32.7K |
| Earning Date | 05-07-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $30,253,000.00 |
| Revenue This Year | N/A | $122.52 |
| Revenue Next Year | $5.25 | $186.30 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.37 | $4.20 |
| 52 Week High | $10.98 | $30.90 |
| Indicator | PRTS | SCLX |
|---|---|---|
| Relative Strength Index (RSI) | 57.67 | N/A |
| Support Level | $0.53 | N/A |
| Resistance Level | $10.98 | N/A |
| Average True Range (ATR) | 0.82 | 0.00 |
| MACD | -0.12 | 0.00 |
| Stochastic Oscillator | 31.01 | 0.00 |
CarParts.com Inc is an online provider of automotive aftermarket parts and repair information. It serves as an end-to-end solution for automotive repair and maintenance resources, offering a seamless online shopping experience that empowers drivers along every part of their journey. The company principally sells its products to individual consumers through its network of websites and online marketplaces. Its products consist of collision parts serving the body repair market, engine parts to serve the replacement parts market, and performance parts and accessories.
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.